ARCHIVES

SEC Notifies ImClone It May Bring Action Against Company

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

Phase III Five-Year Data Show Erbitux Increases Survival Of Head And Neck Cancer

September 26, 2008

Letter To the Editor: Screening Revisited

May 20, 1994

DeVita Accepts “Chop Lie” Cancer Control Elements In CCOP; RFA Delays Until After May NCAB Meeting

March 12, 1982

New Creatinine Test Raises Questions About Accuracy Of Carboplatin Dosing

October 8, 2010

ACS Did Not Sign Bumpers Letter

May 1, 1992

U.S., France Offer Carcinogenesis Program

February 13, 1981